|
|
|
|
|
Gentamicin
drug data and news
Gentamicin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Gentamicin | ||
| Brand Names/Synonyms | Alcomicin; Apogen; Bristagen; CHEMBANK1392; Cidomycin; G-Mycin; G-Myticin; GENTAMYCIN; Garamycin; Garamycin Otic Solution; Garasol; Genoptic; Genoptic Liquifilm; Genoptic S.O.P.; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamcin Sulfate; Gentamicin; Gentamicin Sulfate; Gentamicina [Inn-Spanish]; Gentamicine [Inn-French]; Gentamicins; Gentamicinum [Inn-Latin]; Gentamycin-Creme [German]; Gentamycinum; Gentamysin; Gentavet; Gentocin; HSDB 3087; Isotonic Gentamicin Sulfate in Plastic Container; Jenamicin; Ocu-Mycin; Refobacin; Refobacin Tm; Spectro-Genta; U-Gencin; Uromycine | ||
| Indication | For treatment of serious infections caused by susceptible strains of the following microorganisms: P.aeruginosa, Proteus species (indole-positive and indole-negative), E.coli, Klebsiella-Enterobactor-Serratia species, Citrobacter species and Staphylococcu | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Gentamicin is a broad spectrum aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. | ||
| Mechanism Of Action | Aminoglycosides like Gentamicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Gentamicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. | ||
| Gentamicin News (When available) |
Community-Acquired MRSA a Leading Cause of Skin and Soft-Tissue ... 07 Mar 2006 Innocoll Announces Additional Distribution Agreements in the ... Feb 2, 2006 South Florida-based study on antibiotics could change treatment ... Feb 3, 2006 Europe Adopts GMP Regulations Feb 12, 2006 Innocoll Announces First Asian Distribution Agreement for CollaRx ... Jan 27, 2006 Innocoll Announces Additional Distribution Agreements in the ... Feb 2, 2006 Pediatrix Data Mining Identifies Favorable Antibiotic Combination ... Jan 27, 2006 South Florida-based study on antibiotics could change treatment ... Feb 3, 2006 Some admit working under the influence Jan 16, 2006 AAEP Convention 2004 Wrap-Up 2004: Placentitis Jan 26, 2006 Hospital "super super bug" stronger than MRSA 11 Dec 2005 Superbug worse than MRSA claims 11 hospital victims Dec 9, 2005 Summer superbug cases confirmed Dec 7, 2005 Hospital hit by stronger superbug Dec 7, 2005 Cubist Pharmaceuticals Releases Data from Late Breaker Abstract ... Dec 8, 2005 Pharma warns of fake-drug syndicate Nov 16, 2005 MRSA At Christchurch Women’s Hospital Dec 7, 2005 Adding a Research Component to Clinical Practice Nov 30, 2005 FDA Accepts CUBICIN(R) sNDA and Grants Priority Review Nov 21, 2005 Which end is up? Volunteers help researchers study balance Nov 14, 2005 Artificial Insemination Nov 15, 2005 Bacterial Corneal Ulcers Nov 23, 2005 Doctors claim more scam at city hospital Oct 9, 2005 Cubist Pharmaceuticals Files sNDA to Expand CUBICIN(R) Label for ... Sep 26, 2005 Alleged fake medicines stock GenSan hospitals Oct 7, 2005 Nektar Announces Inhaled Antibiotics Product to Prevent Pneumonia ... Sep 29, 2005 Publix offers flu shots through November Oct 6, 2005 Understanding kidney failure Sep 22, 2005 Safety Biomarkers Help to Reduce Drug Attrition Sep 13, 2005 Analyze This! (Blood Tests Part 2) Sep 8, 2005 Innocoll, Inc. Enters Into Agreement With Medexis for Development ... 08 Sep 2005 Metrohm launches improved Gentamicin detector Sep 5, 2005 Fetus at Risk Sep 2, 2005 Helpful tips for your everyday life Aug 25, 2005 Streptococcus mutans endocarditis: beware of the ‘diphtheroid’ Aug 31, 2005 Innocoll, Inc. Announces Acquisition of Marketing Rights to ... Jul 14, 2005 /CORRECTION -- Innocoll, Inc./ Aug 1, 2005 Chest X-Ray-Confirmed Pneumonia in Children in Fiji Jul 23, 2005 Innocoll, Inc. Enters Into Agreement With Surgical-IOC For ... Jul 28, 2005 AlphaRx Provides Update on Its Antibiotic Development Program Jul 18, 2005 Intussusception complicating typhoid fever Jul 29, 2005 US: unpasteurized Orange Juice Salmonella Typhimurium Outbreak ... Jul 13, 2005 Community-Acquired MRSA: Evolving Pathogens Jul 13, 2005 Journal of the American Podiatric Medical Association Jul 21, 2005 | ||
| Dosage Forms | CREAM; DROPS; IMPLANT; LIQUID; OINTMENT; SOLUTION; SPRAY | ||
| Drug_Category | Anti-bacterial Agents; Anti-bacterial Agents; ATC:D06AX07; ATC:J01GB03; ATC:S01AA11; ATC:S02AA14; ATC:S03AA06 | ||
| Absorption | Injections lead to peak serum concentrations in 30-60 minutes. May also be applied as a topical cream or ophthalmic. The drug is actively transported across the bacterial membrane | ||
| Interactions |
Interactions for Gentamicin: No information provided. | ||
| Toxicity | LD50 = 52 mg/kg (mice, intravenous), 96 mg/kg (rat, intravenous) | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 2-[4,6-diamino-3-[3-amino-6-(1-methylaminoethyl)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-5-methyl-4-methylamino-tetrahydropyran-3,5-diol | ||
| Chemical Formula | C21H43N5O7 | ||
| Molecular Weight | 477.596 g/mol | ||
| Smiles String | CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC | ||
| Melting Point | 218-237 oC (sulfate salt) | ||
| Water Solubility | 100 mg/mL | ||
| State | Solid | ||
| LogP/Hphobicity | -3.637 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 3-3.5 hours | ||
| Protein Binding [%] | Low, between 0 and 30% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Gentamicin.html http://www.rxlist.com/cgi/generic2/pedgenta.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/gar1187.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00214 | ||
| CAS Registry Number | 1403-66-3 | ||
| KEGG Compound ID | C00505 | ||
| PubChem ID | SID:3788 | ||
| PharmGKB ID | PA449753 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 776521 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |